Skip Navigation


Cardiovascular Research Advance Access first published online on February 15, 2008
This version [Corrected Proof] published online on March 14, 2008

Cardiovascular Research, doi:10.1093/cvr/cvn041
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
78/3/505    most recent
cvn041v2
cvn041v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Oudit, G. Y.
Right arrow Articles by Penninger, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oudit, G. Y.
Right arrow Articles by Penninger, J. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress

Gavin Y. Oudit1,2,*, Zamaneh Kassiri2,3, Joyce Zhou4, Qiao C. Liu4, Peter P. Liu1, Peter H. Backx1, Fayez Dawood1, Michael A. Crackower5, James W. Scholey4 and Josef M. Penninger6

1 Division of Cardiology, Department of Medicine, Rm 7326, Medical Sciences Building, One King’s College Circle, University of Toronto, Toronto, Canada M5S 1A8
2 Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada
3 Department of Physiology, University of Alberta, Edmonton, Alberta, Canada
4 Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Canada
5 Merck Frosst Center for Therapeutic Research, Quebec, Canada
6 IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria

* Corresponding author. Tel: +1 416 340 5093; fax: +1 416 340 4999. E-mail address: gavin.oudit{at}utoronto.ca

Aims: The maladaptive response to biomechanical stress is a fundamental response in heart disease. Loss of the 3'-lipid phosphatase, phosphatase and tensin homolog deleted on chromosome ten (PTEN), is associated with increased phosphorylation of Akt/protein kinase B and glycogen synthase kinase-β. We hypothesize that these key changes will halt the development of pathological hypertrophy and the progression to heart failure in response to pressure overload.

Methods and results: In mice, muscle-specific knockout of PTEN, mckCRE-PTENflox/flox (PTEN KO), resulted in basal hypertrophy and mild reduction in left ventricular (LV) systolic function. Male mice were subjected to aortic banding (AB) or sham operation. In contrast to mckCRE-PTEN+/+ control mice, pressure overload in PTEN KO mice resulted in reduced pathological hypertrophy, less interstitial fibrosis, and reduced apoptosis with a marked preservation of LV function. Western blot analysis of mitogen-activated protein kinase (MAPK) signalling showed equivalent phosphorylation of extracellular signal-regulated kinase (ERK)1 and ERK2 with markedly reduced phosphorylation of jun N-terminal kinase (JNK)1 and JNK2, and p38 in PTEN KO mice subjected to AB. Loss of PTEN was associated with increased expression of the proangiogenic factors, vascular endothelial growth factor-A and angiopoietin-2, with preservation of the myocardial capillary density in response to pressure overload. Moreover, banded PTEN KO mice maintained the expression of several key metabolic genes that are known to be dysregulated in heart failure. In contrast, a subpressor dose of the G protein-coupled receptor (GPCR) agonist angiotensin II (Ang II) leads to increased pathological hypertrophy and MAPK activation in PTEN KO mice.

Conclusion: Loss of PTEN prevents the development of maladaptive ventricular remodelling with preservation of angiogenesis and metabolic gene expression in response to pressure overload but not in response to the GPCR agonist, Ang II. Inhibition of PTEN signalling in the heart may represent a novel approach to slow the progression of heart failure in response to pathological biomechanical stress.

KEYWORDS Heart failure; Hypertrophy; Angiogenesis; Angiotensin II; Signalling


Time for primary review: 28 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. X. Fang, F. Dong, D. P. Thomas, H. Ma, L. He, and J. Ren
Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1206 - H1215.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.